Twist Bioscience Corporation (TWST) reported Q4 EPS of ($0.91), $0.36 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.78 million.
GUIDANCE:
Twist Bioscience Corporation sees Q1 2023 revenue of $54 million, versus the consensus of $57 million.
Twist Bioscience Corporation sees FY2023 revenue of $261-269 million, versus the consensus of $256 million.
- Revenue is expected to be in the range of $261 million to $269 million
- SynBio revenue is expected to be in the range of $104 million to $106 million
- NGS revenue is expected to be in the range of $120 million to $123 million
- Biopharma revenue is expected to be in the range of $37 million to $40 million
- Gross margin is expected to be approximately 39-40% for fiscal 2023
- Operating expenses including R&D and SG&A are expected to be approximately $365 million for the year
- R&D expense is expected to be approximately $138 million
- Net loss is expected to be approximately $260 million and includes:
- Stock-based compensation is expected to be approximately $83 million
- Depreciation and amortization is expected to be approximately $26 million
- Operating expenses for DNA data storage of approximately $46 million
- Capital expenditure is expected to be approximately $50 million
- FY23 Year End Cash projected to be $300M